Press release
AL Amyloidosis Pipeline and Clinical Trials Assessment (2023) | Companies- Caelum Biosciences, Nexcella, Inc., HaemaLogiX Ltd., Prothena, Zentalis Pharmaceuticals, Sorrento Therapeutics, Inc., and others
AL Amyloidosis Pipeline
The AL Amyloidosis pipeline analysis report for AL Amyloidosis emerging drugs offers a comprehensive and holistic perspective of the therapeutic landscape. It encompasses the development stage, product type, route of administration, molecule type, and mechanism of action (MOA). The research on the AL Amyloidosis pipeline covers multiple facets including business opportunities, challenges, potential partnerships, formidable competitors, and growth strategies. Each drug is described in detail, including its mechanism of action, AL Amyloidosis clinical trial studies conducted for AL Amyloidosis, any obtained AL Amyloidosis NDA approvals, and product development activities such as technology, collaborations, licensing, mergers and acquisitions, funding, designations, and other pertinent information.
To explore more information on the latest breakthroughs in the AL Amyloidosis Pipeline treatment landscape of the report, click here @ AL Amyloidosis Pipeline Outlook- https://www.delveinsight.com/sample-request/al-amyloidosis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Key Takeaways from the AL Amyloidosis Pipeline Report
• DelveInsight's AL Amyloidosis Pipeline analysis depicts a robust space with 10+ active players working to develop 10+ pipeline treatment therapies.
• The leading AL Amyloidosis Companies are working in the market include Caelum Biosciences, Nexcella, Inc., HaemaLogiX Ltd., Prothena, Zentalis Pharma, Sorrento Therapeutics, Inc., and others.
• Promising AL Amyloidosis Pipeline Therapies in the various stages of development include CAEL-101, Daratumumab, Ixazomib, Cyclophosphamide, Dexamethasone, Bendamustine, Pomalidomide, NEOD001, Siltuximab and others.
• CAEL-101 is a fibril-reactive monoclonal antibody (mAb) that is currently in Phase III clinical development for the treatment of patients with amyloid light chain ("AL") amyloidosis. The Cardiac Amyloid Reaching for Extended Survival (CARES) clinical program includes two parallel Phase III studies - one in patients with Mayo stage IIIa disease and one in patients with Mayo stage IIIb disease - and will collectively enroll approximately 370 patients globally. Enrollment is underway in both studies. The primary objective of the clinical program is to assess overall survival. CAEL-101 has received Orphan Drug Designation from both the U.S. Food and Drug Administration and European Medicine Agency as a therapy for patients with AL amyloidosis.
• NXC-201 (formerly HBI0101) is a BCMA-targeted investigational chimeric antigen receptor T (CAR-T) cell therapy that is being studied in a comprehensive clinical development program for the treatment of patients with relapsed or refractory multiple myeloma and AL amyloidosis. The design consists of a structurally differentiated CAR-T, with the proprietary BCMA-targeting CAR, which has demonstrated reduced toxicity in NEXICART-1, supporting investigating NXC-201 as an outpatient therapy. It is currently in Phase I NEXICART-1 study of its novel, autologous, BCMA-targeted chimeric antigen receptor T (CAR-T) cell therapy for the treatment of patients with relapsed or refractory multiple myeloma and light chain amyloidosis (AL).
AL Amyloidosis Overview
AL amyloidosis is the most common type, with approximately 4,500 new cases diagnosed every year. It usually affects people from ages 50-80, although there are a few cases of people being diagnosed as early as their late 20s. About two-thirds of the patients are male. AL amyloidosis is caused by a bone marrow disorder. The bone marrow in the center of bones produces cells in the blood system, including "plasma cells." These plasma cells are the part of the immune system that makes antibodies for fighting infections.
For further information, refer to the detailed AL Amyloidosis Unmet Needs, AL Amyloidosis Market Drivers, and AL Amyloidosis Market Barriers, click here for AL Amyloidosis Ongoing Clinical Trial Analysis- https://www.delveinsight.com/sample-request/al-amyloidosis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
AL Amyloidosis Emerging Drugs Profile
• CAEL-101: Caelum Biosciences
• NXC-201: Nexcella, Inc.
AL Amyloidosis Pipeline Therapeutics Assessment
There are approx. 10+ AL Amyloidosis companies which are developing the therapies for AL Amyloidosis. The companies which have their AL Amyloidosis drug candidates in the most advanced stage, i.e. phase III.
Request a sample and discover the recent advances in AL Amyloidosis Ongoing Clinical Trial Analysis and Medications, click here @ AL Amyloidosis Treatment Landscape- https://www.delveinsight.com/sample-request/al-amyloidosis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
AL Amyloidosis Pipeline Segmentation
• Assessment by Product Type
• Assessment by Stage and Product Type
• Assessment by Route of Administration
• Assessment by Stage and Route of Administration
• Assessment by Molecule Type
• Assessment by Stage and Molecule Type
Some of the Companies in the AL Amyloidosis Therapeutics Market include-
Caelum Biosciences, Nexcella, Inc., HaemaLogiX Ltd., Prothena, Zentalis Pharma, Sorrento Therapeutics, Inc., and others.
Dive deep into rich insights for drugs for AL Amyloidosis Pipeline, click here @ AL Amyloidosis Unmet Needs and Analyst Views- https://www.delveinsight.com/sample-request/al-amyloidosis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Scope of the AL Amyloidosis Pipeline Report
• Coverage- Global
• AL Amyloidosis Companies- Caelum Biosciences, Nexcella, Inc., HaemaLogiX Ltd., Prothena, Zentalis Pharma, Sorrento Therapeutics, Inc., and others.
• AL Amyloidosis Pipeline Therapies- CAEL-101, Daratumumab, Ixazomib, Cyclophosphamide, Dexamethasone, Bendamustine, Pomalidomide, NEOD001, Siltuximab and others.
• AL Amyloidosis Pipeline Segmentation: Product Type, Molecule Type, Route of Administration
Got Queries? Find out the related information on AL Amyloidosis Mergers and acquisitions, AL Amyloidosis Licensing Activities @ AL Amyloidosis Emerging Drugs, and Recent Trends- https://www.delveinsight.com/sample-request/al-amyloidosis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Table of Content
1. Introduction
2. AL Amyloidosis Executive Summary
3. AL Amyloidosis: Overview
4. AL Amyloidosis Pipeline Therapeutics
5. AL Amyloidosis Therapeutic Assessment
6. AL Amyloidosis- DelveInsight's Analytical Perspective
7. Late Stage Products (Phase III)
8. CAEL-101: Caelum Biosciences
9. AL Amyloidosis Drug profiles in the detailed report…..
10. Mid Stage Products (Phase II)
11. Drug Name: Company Name
12. Drug profiles in the detailed report…..
13. Early Stage Products (Phase I)
14. NXC-201: Nexcella, Inc.
15. Drug profiles in the detailed report…..
16. Preclinical and Discovery Stage Products
17. LambdaMab 10B3 & 7F11: HaemaLogiX Ltd.
18. Drug profiles in the detailed report…..
19. Inactive Products
20. AL Amyloidosis Key Companies
21. AL Amyloidosis Key Products
22. AL Amyloidosis- Unmet Needs
23. AL Amyloidosis- Market Drivers and Barriers
24. AL Amyloidosis- Future Perspectives and Conclusion
25. AL Amyloidosis Analyst Views
26. AL Amyloidosis Key Companies
27. Appendix
About Us
DelveInsight is a leading healthcare focussed market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: ybhardwaj@delveinsight.com
Phone: 9193216187
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/consulting-services
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release AL Amyloidosis Pipeline and Clinical Trials Assessment (2023) | Companies- Caelum Biosciences, Nexcella, Inc., HaemaLogiX Ltd., Prothena, Zentalis Pharmaceuticals, Sorrento Therapeutics, Inc., and others here
News-ID: 3081415 • Views: …
More Releases from DelveInsight Business Research
Gastric Cancer Market to Exceed USD 700 Million in HER2+ Segment by 2034 Across …
Gastric cancer is the fifth most common malignancy worldwide, with incidence varying by region and highest rates reported in Eastern Asia and Eastern Europe. Japan records the highest burden among the 7MM, with about 129,500 cases in 2024. Many patients, particularly in Western countries, are diagnosed at advanced (Stage IV) stages, while Japan detects more cases early (Stage I). In the US, around 35% present with metastatic disease at diagnosis,…
Myelofibrosis Market to Double by 2034, Surpassing USD 5.6 Billion Across 7MM wi …
The Myelofibrosis market across the seven major markets (7MM) is anticipated to experience significant growth, rising from approximately USD 2,602 million in 2025 to nearly USD 5,638 million by 2034, reflecting a compound annual growth rate (CAGR) of about 9% during the forecast period.
In 2024, the market was valued at around USD 2.2 billion, with the United States leading at nearly USD 1.7 billion, far surpassing the EU4, the United…
Triple-Negative Breast Cancer Clinical Trial Landscape Expands With 170+ Pipelin …
An expanding portfolio of novel therapies for triple-negative breast cancer (TNBC) including TECENTRIQ (Hoffmann-La Roche), IPI-549 (Infinity Pharmaceuticals), Leronlimab (CytoDyn), MDNA11 (Medicenna Therapeutics), VIP236 (Vincerx Pharma), and CFI-400945 (Treadwell Therapeutics) is anticipated to significantly influence market expansion and transform the TNBC treatment landscape.
DelveInsight's Triple Negative Breast Cancer Pipeline Insight report offers an extensive evaluation of more than 165 companies and over 170 therapeutic candidates advancing through the TNBC pipeline. The…
Asthma Market to Witness Steady Growth Through 2034 Driven by Novel Biologics an …
DelveInsight's latest Asthma Market Insights, Epidemiology, and Market Forecast - 2034 report provides an in-depth evaluation of current treatment practices, emerging asthma drugs, market share of individual therapies, and forecasted market trends across the seven major markets (7MM) - the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan.
The asthma market is expected to experience sustained growth over the next decade, supported by the launch of…
More Releases for Amyloid
Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market Forecast 2034: I …
DelveInsight's newly published report, "Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Market Insights, Epidemiology, and Market Forecast - 2032," delivers a comprehensive assessment of the ATTR-CM market across the seven major markets (7MM), encompassing the United States, EU4, the United Kingdom, and Japan. The report offers detailed insights into disease epidemiology, evolving treatment approaches, and shifting market trends, with projections extending through 2032.
Intellia Therapeutics recently reported promising longer-term Phase 1 outcomes for its…
Cerebral Amyloid Angiopathy Pipeline Landscape: 10+ Emerging Therapies Targeting …
Cerebral Amyloid Angiopathy (CAA) is a progressive cerebral small vessel disease marked by amyloid-β (Aβ) protein deposition in the walls of leptomeningeal and cortical blood vessels. Often occurring in the elderly and closely linked with Alzheimer's disease, CAA contributes significantly to cognitive impairment, spontaneous intracerebral hemorrhage, and cerebral microbleeds. Despite its high clinical burden, there are currently no approved disease-modifying therapies specifically for CAA, and diagnosis remains challenging without advanced…
Amyloid Peptides Market to Witness Astonishing Growth by 2029
Amyloid Peptides Market is anticipated to grow at a significant CAGR during the forecast period. Growing favourable investment, as well as reimbursement facilities in the developed economic countries, is one of the major factors that is expected to fuel the global amyloid peptides market during the forecast period. Moreover, a growing number of clinical trials and research activities to develop treatment and drugs for Alzheimer's are also anticipated to boost…
Amyloid Peptides Market Size, Share, Development by 2024
Global Info Research offers a latest published report on Amyloid Peptides Market Analysis and Forecast 2019-2025 delivering key insights and providing a competitive advantage to clients through a detailed report. This report focuses on the key global Amyloid Peptides players, to define, describe and analyze the value, market share, market competition landscape, SWOT analysis and development plans in next few years.
To analyze the Amyloid Peptides with respect to individual growth…
Islet Amyloid Polypeptide: Therapeutic Developments to Witness Growth
Islet Amyloid Polypeptide (Amylin or Diabetes Associated Peptide or Insulinoma Amyloid Peptide or IAPP) - Islet amyloid polypeptide (IAPP) or Amylin is a peptide hormone. This hormone is released from pancreatic beta cells following food intake to regulate blood glucose levels and act as a satiation signal. It inhibits insulin-stimulated glucose utilization and glycogen deposition in muscle. The molecules developed by companies in Phase II, Phase I and Preclinical stages…
Islet Amyloid Polypeptide: Therapeutic Developments to Witness Growth
Islet Amyloid Polypeptide (Amylin or Diabetes Associated Peptide or Insulinoma Amyloid Peptide or IAPP) - Islet amyloid polypeptide (IAPP) or Amylin is a peptide hormone. This hormone is released from pancreatic beta cells following food intake to regulate blood glucose levels and act as a satiation signal. It inhibits insulin-stimulated glucose utilization and glycogen deposition in muscle. The molecules developed by companies in Phase II, Phase I and Preclinical stages…
